ERIS Lifesciences Ltd

ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change has prompted a downgrade in its Mojo Grade from Hold to Sell, signalling increased caution among investors despite the company’s solid operational metrics and long-term returns outperforming the Sensex.

ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, signalling improved price attractiveness for investors. Despite recent headwinds reflected in its share price performance, the company’s relative valuation metrics now present a more balanced risk-reward profile compared to its pharmaceutical peers and historical averages.

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with the latest insights into its performance and outlook.

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, as reflected in recent indicator readings. Despite a 3.07% gain on 24 Apr 2026, the stock’s technical parameters present a complex picture, with mixed signals from MACD, RSI, moving averages, and other key indicators, suggesting cautious optimism amid underlying challenges.

ERIS Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 09 Feb 2026. The stock’s recent price action and technical indicators suggest increasing bearish pressure, with the share price declining 2.45% on 23 Apr 2026 to ₹1,344.50, reflecting a broader trend of weakening momentum.

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

ERIS Lifesciences Ltd has experienced a subtle yet notable shift in its technical momentum, moving from a bearish to a mildly bearish stance. Despite a modest day gain of 0.93%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages, and other momentum oscillators. This analysis delves into the recent technical parameter changes, placing them in the context of the company’s price action and broader market trends.

ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from a fair to an expensive rating. This change, coupled with a downgrade in its overall Mojo Grade from Hold to Sell, highlights growing concerns about the stock’s price attractiveness relative to its historical and peer benchmarks. Investors should carefully analyse these valuation dynamics amid the company’s performance and sector trends.

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, returns, and market standing.

ERIS Lifesciences Ltd has witnessed a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change has prompted a downgrade in its Mojo Grade from Hold to Sell, signalling a reassessment of its price attractiveness amid evolving market dynamics and peer comparisons within the Pharmaceuticals & Biotechnology sector.

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the small-cap pharmaceutical player in a new light for investors seeking value within the Pharmaceuticals & Biotechnology sector.

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into its performance and outlook.

ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions and adjustments in key financial ratios such as the price-to-earnings (P/E) and price-to-book value (P/BV) multiples. Investors analysing ERIS Lifesciences must consider these valuation dynamics in the context of its sector peers and historical performance to gauge the stock’s price attractiveness and future potential.

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 21 February 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.